Clinical trials: Osteoporosis Postmenopausal
Post Menopausal Osteoporosis
Study of the Impact of Mother-of-pearl Nutritional Supplementation on the Prevention of Post-menopausal Osteoporosis
Post-menopausal osteoporosis and the resulting fractures are an important cause of disability and loss of independence. They also increase the risk of morbidity and mortality.
- Trial name
- NUTRANACRE (NCT05571514)
- Testing
- Mother-of-pearl, Calcium Carbonate
- Where
- 7 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Osteoporosis, Postmenopausal
Dental Panoramic Radiographs to Screen for Post-menopausal Osteoporosis
Osteoporosis is a common disease that makes the bones fragile and easy to break. Osteoporotic fractures are a serious health problem resulting in pain, reduced mobility, increasing degree of dependence and sometimes death.
- Trial name
- OsteoPano (NCT03304743)
- Testing
- Dental panoramic radiograph
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University of Parma
Post Menopausal Osteoporosis
Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis
To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when…
- Trial name
- NCT01674621
- Testing
- Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg)
- Where
- 9 sites in United States, Denmark and 2 more
- Volunteers
- 250 people
- Sponsor
- Radius Health, Inc.
Osteoporosis
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
This is a Multi-Center, Randomized, Double-Blind, Dose Escalation, Placebo Parallel Controlled PhaseⅠClinical study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics, Immunogenicity with Multiple…
- Trial name
- NCT04435158
- Testing
- SHR-1222
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Osteoporosis
Green Tea and Tai Chi for Bone Health
Osteoporosis is a major health problem in postmenopausal women. Our long-term goal is to develop a new alternative treatment that include a dietary supplement (green tea extract) and a mind-body exercise (Tai Chi) for lessening…
- Trial name
- GTP-TC-Bone (NCT00625391)
- Testing
- Green Tea Polyphenols (GTP), GTP+TC
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Osteoporosis
Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.
- Trial name
- NCT00936260
- Testing
- alendronate
- Where
- Spain
- Volunteers
- 228 people
- Sponsor
- Ciudad Universitaria, Spain
Hypercalciuria, Hypercalciuria, Familial Idiopathic
The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass
The purpose of this study is to assess if estrogen replacement normalizes urinary calcium excretion in postmenopausal women with hypercalciuria and low bone mass and to assess for differences in response to estrogen replacement…
- Conditions
- Hypercalciuria, Hypercalciuria, Familial Idiopathic, Osteopenia, Osteoporosis
- Trial name
- NCT01928082
- Testing
- Transdermal estradiol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Osteoporosis
Bone Effects of Teriparatide Following Alendronate
The purpose of this study is to assess the effect of 24 months of treatment with once daily teriparatide injection (recombinant human PTH [1-34]) 20 micrograms on bone histomorphometry and architecture.
- Trial name
- NCT00191893
- Testing
- teriparatide
- Where
- 2 sites in Austria, Czechia
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Osteoporosis in Post-menopausal Women, Prevention
Development of a Wearable Device for Osteoporosis Prevention and Fracture Risk Reduction in Women
This project aims to determine the impact on bone health of: A lifestyle intervention promoting impact-based activities and physical activity for nine months. The same program enhanced with home-based strength training.
- Conditions
- Osteoporosis in Post-menopausal Women, Prevention, Exercise, Physical Activity
- Trial name
- Weapom (NCT06741956)
- Testing
- Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Seville
Osteoporosis
Balance and Muscle Strength as Indicators of Fracture Risk in Postmenopausal Women
The study is designed as a cross-sectional clinical study. A total of 156 postmenopausal women who visited the Physical Therapy and Rehabilitation outpatient clinic at Beylikdüzü State Hospital and have had Dual X-ray…
- Trial name
- NCT06645600
- Testing
- Fracture risk
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Beylikduzu State Hospital
Bone Diseases, Cardiovascular Diseases
CVD Risk and Health in Postmenopausal Phytoestrogen Users
To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.
- Conditions
- Bone Diseases, Cardiovascular Diseases, Coronary Disease, Depression
- Trial name
- NCT00000613
- Testing
- dietary supplements, genistein, diet, soy proteins
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Osteoporosis
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
The primary objective of this study is to assess the effect of AMG 162 (denosumab) treatment on the lumbar spine BMD at month 12 and safety profile across the dose range tested (14, 60 and 100 mg SC once every 6 months) in…
- Trial name
- NCT00306189
- Testing
- 100 mg AMG 162, 60 mg AMG 162, 14 mg AMG 162
- Volunteers
- 212 people
- Sponsor
- Amgen
Postmenopausal Osteopenia, Quality of Life
Translation and Cross -Cultural Validation of ECOS-16 Questionnaire in Urdu Language
Osteopenia is a clinical term to define the declined Bone Mineral Density (BMD) as per the normal reference values but not low enough to meet osteoporotic diagnostic criteria.
- Conditions
- Postmenopausal Osteopenia, Quality of Life, Validity, Reliability
- Trial name
- NCT04873960
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Riphah International University
Hypovitaminosis D, Osteoporosis, Postmenopausal
Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy.
- Conditions
- Hypovitaminosis D, Osteoporosis, Postmenopausal, Menopause
- Trial name
- NCT05372224
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 55 people
- Sponsor
- Hospital Regional 1o de Octubre
Osteoporosis
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)
The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy.
- Trial name
- NCT00118508
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Pittsburgh
Osteoporosis
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
The purpose of this study is to assess the clinical efficacy, safety, and tolerability of ViaDerm-shPTH [1-34] transdermal delivery in comparison to subcutaneous injection of rhPTH[1-34] following 3-month treatment in…
- Trial name
- NCT00535860
- Testing
- Teriparatide
- Where
- 10 sites in Czechia, Hungary and 1 more
- Volunteers
- 104 people
- Sponsor
- TransPharma Medical
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00688246
- Testing
- biologic sample preservation procedure, dual x-ray absorptometry
- Where
- 18 sites in United States, Canada
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- NCIC Clinical Trials Group
Perimenopausal Bone Loss, Postmenopausal Osteopenia
Prevention of Osteoporosis: Effects of Mini-trampoline Training on the Bone Remodeling
The aim of the project is to study the effects on bone remodeling induced by training carried out with the trampoline in order to evaluate the reduction of the resorption itself and therefore the onset of osteoporosis in women.
- Trial name
- TRAMBONE (NCT04942691)
- Testing
- physical activity
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Osteoporosis
Tocotrienols and Bone Health of Postmenopausal Women
Osteoporosis (severe bone loss) is a bone disease with bone fragility and an increased chance for bone fractures. Recent studies have indicated tocotrienols (one kind of vitamin E) supplement may be good for the bone health in…
- Trial name
- NCT02058420
- Testing
- Low tocotrienols group, High tocotrienols group
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.